KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Deferred Tax (2023 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Long-Term Deferred Tax for 8 consecutive years, with $117.0 million as the latest value for Q1 2026.

  • For Q1 2026, Long-Term Deferred Tax rose 9.08% year-over-year to $117.0 million; the TTM value through Mar 2026 reached $117.0 million, up 9.08%, while the annual FY2025 figure was $126.0 million, 7.8% up from the prior year.
  • Long-Term Deferred Tax hit $117.0 million in Q1 2026 for Alnylam Pharmaceuticals, down from $126.0 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $126.0 million in Q4 2025 and bottomed at $10.1 million in Q4 2023.
  • Average Long-Term Deferred Tax over 4 years is $97.1 million, with a median of $107.2 million recorded in 2025.
  • Year-over-year, Long-Term Deferred Tax surged 1056.94% in 2024 and then increased 7.8% in 2025.
  • Alnylam Pharmaceuticals' Long-Term Deferred Tax stood at $10.1 million in 2023, then soared by 1056.94% to $116.9 million in 2024, then increased by 7.8% to $126.0 million in 2025, then decreased by 7.16% to $117.0 million in 2026.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $117.0 million, $126.0 million, and $98.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.